HOME >> BIOLOGY >> NEWS
Positive attitude is best prevention against heart disease

"This study has the potential to change how emergency departments triage patients with chest pain." Nisha Chandra-Stobos, M.D.

For years, hospital emergency physicians have used nitrogylcerin as a gold standard for identifying heart disease as a cause of chest pain. If a patient presents with chest pain, and a nitroglycerin pill or spray under the tongue relieves the pain within a few minutes, the likely diagnosis is coronary artery disease (CAD).

Now a Johns Hopkins study is challenging that belief. Of 459 patients who came to the emergency department at Hopkins' Bayview Medical Center between February and June of this year complaining of chest pain, nitroglycerin relieved chest pain in about 39 percent of patients, whether or not they turned out to have heart disease. Overall, nitroglycerin was only 28 percent accurate in predicting CAD as the source of pain. These findings will be presented Nov. 12 at the American Heart Association's annual Scientific Sessions in Anaheim, Calif.

"This study has the potential to change how emergency departments triage patients with chest pain," says Nisha Chandra-Stobos, M.D., senior author of the study and director of the coronary intensive care unit at Bayview. "Our data suggest that despite the commonly held belief, pain relief with nitroglycerin does not predict coronary artery disease and should not be used to guide diagnosis."

Nitroglycerin works by relaxing the veins (reducing the amount of blood that returns to the heart and easing the heart's workload) and arteries (increasing the heart's blood supply). It's the drug most often used for the one in five patients who comes to the ED complaining of chest pain.

The patients studied had an average age of 58. Forty-six percent were male; 44 percent were smokers; 25 percent were diabetic and 38 percent had a known history of CAD. After initial treatment with nitroglycerin, 261 (57 percent) underwent further cardiac test
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
13-Nov-2001


Page: 1 2

Related biology news :

1. Positive attitude is best prevention against heart disease
2. Nationwide Study Finds HIV-Positive Women Are At High Risk For Cervical Human Papillomavirus Infection
3. Native Gray Ants Play Positive Role In Valley Peach Orchards
4. Drug Therapy Shows Promise In Preventing Hepatitis Infection In Transplant Recipients Who Receive Hepatitis B Positive Livers, Says One Study
5. HIV-Positive Injection Drug Users Often Dont Receive Protease Inhibitors And May Not Be Aware Of The Drug
6. Long-Term Study Looks At HIV Positive Men With Few Signs Of Disease Progression, 10-18 Years After Seroconversion
7. Study finds wide attitude gap on wolves
8. Study reveals differing attitudes to PGD among
9. Heritability of attitudes: Twin research in religious perspective
10. Scholar finds parallels between U.S./Japanese attitudes toward wolves
11. Cranfield looks at recycling attitudes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive attitude best prevention against heart disease

(Date:10/15/2014)... to bacterial pneumonia in female mice to an enzyme ... are naturally more resistant to respiratory infections than males. ... increased resistance to bacterial pneumonia in female mice is ... They also show that this enzyme is ultimately activated ... , The team, lead by Professor Lester Kobzik at ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
(Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: